In Wilmington, Delaware, AstraZeneca and Daiichi Sankyo have received approval in the United States for their drug ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, confirmed by an FDA-approved test. This approval, following Priority Review and Breakthrough Therapy Designation by the FDA, is based on findings from the DESTINY-Breast09 Phase III trial.